Macular Disease Foundation Australia logo

    Third anti-VEGF agent reimbursed by PBS

    Beovu® to be subsidized by the Pharmaceutical Benefits Scheme.

    Image of an older guy holding his glasses and looking at the camera

    On 1st October 2021, Beovu® (brolucizumab) became the third anti-VEGF drug to be subsidised by the Pharmaceutical Benefits Scheme (PBS) for the treatment of wet (neovascular) age-related macular degeneration.

    In the announcement, the Health Minister The Hon Greg Hunt MP highlighted AMD as responsible for half of all blindness and serious vision loss in Australia.

    Beovu® is only available for patients who have received Lucentis® (ranibizumab) and/or EYLEA® (aflibercept) for at least six months and have not responded to first-line treatment.

    The decision to switch between anti-VEGF therapies requires careful consideration of risks and benefits. For patients currently receiving eye injections for wet AMD, your ophthalmologist will be able to discuss with you whether the new treatment may be appropriate or not.

    Posted: 18 October 2021

    We think you might also be interested in…

    New gene therapy for AMD

    MDFA funded researcher, Dr Yvette Wooff is investigating cell particles called extracellular vesicles (EV), which could help develop novel gene therapies for dry AMD.

    More articles like this